Evidence map›Paper›PMID 34013494›Full record

ArticleNeurogenetics2021

More evidence on TRIO missense mutations in the spectrin repeat domain causing severe developmental delay and recognizable facial dysmorphism with macrocephaly.

K Kloth, L Graul-Neumann, K Hermann, J Johannsen, T Bierhals, F Kortüm

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. De NovoHuman mutation · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

K KlothInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.kloth-stachnau@uke.de.
L Graul-NeumannAmbulantes Gesundheitszentrum Humangenetik, Charité Universitaetsmedizin Berlin, Berlin, Germany.
K HermannDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J JohannsenDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
T BierhalsInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
F KortümInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRIO is a Dbl family guanine nucleotide exchange factor (GEF) and an important regulator of neuronal development. Most truncating and missense variants affecting the Dbl homology domain of TRIO are associated with a neurodevelopmental disorder with microcephaly (MIM617061). Recently, de novo missense variants affecting the spectrin repeat region of TRIO were associated with a novel phenotype comprising severe developmental delay and macrocephaly (MIM618825). Here, we provide more evidence on this new TRIO-associated phenotype by reporting two severely affected probands with de novo missense variants in TRIO affecting the spectrin repeat region upstream of the typically affected GEF1 domain of the protein.

Indexed as

Guanine Nucleotide Exchange FactorsHumansMegalencephalyMicrocephalyMutation, MissenseNeurodevelopmental DisordersPhenotypeProtein Serine-Threonine KinasesSpectrinGuanine Nucleotide Exchange FactorsProtein Serine-Threonine KinasesSpectrinTRIO protein, humanDevelopmental delayFacial dysmorphismGenotype–phenotype correlationMacrocephalyNeurocognitive disorderRAC1TRIO

Identifiers

PMID34013494
OpenAlexW3162394537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.